Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CPA3 | P15088 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799260 | 1.00 | ACE (0.64) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL883357 | 0.84 | SLC1A3 (0.63) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL5511480 | 0.84 | SLC1A3 (0.63) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL7052531 | 0.84 | CPB2 (0.57) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL305323 | 0.83 | SLC1A3 (0.73) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL7289849 | 0.83 | SLC1A3 (0.73) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL2919214 | 0.83 | SLC1A3 (0.73) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL4755513 | 0.83 | SLC1A3 (0.73) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL24252143 | 0.82 | SLC1A3 (0.61) | ACESLC1A3SLC1A2SLC1A1CPB2 | |
| SCHEMBL5708390 | 0.82 | SLC1A3 (0.61) | ACESLC1A3SLC1A2SLC1A1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | NYSNOBIO IRELAND DAC (IE) | 2020-03-19 | — | — | US | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087648-A1 | PARKIN LIGASE ACTIVATION METHODS AND COMPOSITIONS | PINK1, XIAP, STUB1 | ACE 3033/4885SLC1A3 3852/4885SLC1A2 3958/4885 |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | ACE 100/4885SLC1A3 2231/4885SLC1A2 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.